新型冠状病毒

Lex Letter from Seoul: China’s vaccines and efficacy rates

Demand for Sinovac’s CoronaVac will remain high. In most developing countries, it is the only option

Dear readers,

Who will get immunised first — or at all — is a hot topic of conversation worldwide. Vaccine shortages add to the uncertainty. Covid-19 shot manufacturers such as Pfizer are hitting production limits. But in Asia, Chinese vaccine makers have no problem meeting demand.

State-owned Sinopharm and Sinovac have shipped more than 20m doses to developing countries including Turkey, Brazil, the Philippines and Thailand. The two businesses have signed deals to provide hundreds of millions of further doses. More than 15m shots have been administered in China, according to the National Health Commission.

您已阅读17%(612字),剩余83%(2908字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×